Get notified when AVLN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Fraud / investigation
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Material Weakness (new) — The company discloses the possibility of material weaknesses in internal controls over financial reporting, which could result in a material misstatement of financial statements.
- Concentration (new) — The company is substantially dependent on the success of its lead candidates AP01 and AP02, and relies on a sole supplier for certain manufacturing steps and on licensed PARI device technology.
Avalyn Pharma files for IPO, plans to raise $283.3M at $17.00/share midpoint
Filed April 29, 2026 · ~2 min read
Key Changes
-
high
Avalyn Pharma plans to offer 16,666,667 shares of voting common stock at a preliminary price of $17.00 per share, the midpoint of the range, for gross proceeds of $283.3M.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $258.7M, after underwriting discounts and expenses, with an option for underwriters to purchase up to 2,500,000 additional shares.
Use of Proceeds verify on EDGAR → -
high
The company plans to use approximately $150M for AP01, $90M for AP02, and $10M for AP03 development, with the remainder for other R&D and general corporate purposes.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade AVLN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify